when will semaglutide go generic FDA has not approved a generic version of Ozempic - Semaglutidepatent expiry Semaglutide When Will Semaglutide Go Generic? A Global Outlook on Patent Expirations and Market Entry

Mounjaro patent expiration The landscape of diabetes and weight management treatments is on the cusp of a significant shift. As the patent for semaglutide, the active ingredient in popular brand-name drugs like Ozempic and Wegovy, approaches expiration in key global markets, the anticipation for generic semaglutide is mounting. This article delves into the projected timeline for semaglutide patent expiry across different regions, explores the companies poised to enter the market, and discusses the potential impact on drug accessibility and cost.2025年11月14日—Even global players like Dr Reddy's Laboratories have outlined ambitions to launch generics in 87 countries, including Canada, as early as March ...

Understanding Semaglutide and its Patent Protection

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the action of the GLP-1 hormone in the body.2026年1月14日—Patent expires in 2031 in "the majority of EU member states," according to Novo. Canada — currently the second-largest market forsemaglutide, ... It plays a crucial role in regulating blood sugar levels by stimulating insulin secretion, reducing glucagon release, and slowing gastric emptying, which contributes to feelings of fullness. These mechanisms have made it a groundbreaking treatment for type 2 diabetes and, more recently, for chronic weight management.

However, like all patented pharmaceuticals, semaglutide is protected by intellectual property rights owned by its developer, Novo Nordisk.2026年1月2日—Drug companies in Canada are allowed to make lower priced generic versions of the blockbuster drug Ozempic as ofnext week, but experts say ... These patents grant exclusive marketing rights for a specified period, preventing other manufacturers from producing and selling generic versions. The expiration of these patents is the critical trigger for the availability of more affordable generic alternatives.

Global Patent Expirations: A Market-by-Market Breakdown

The when will semaglutide go generic question has varied answers depending on the geographical region. While the US patent protection for semaglutide extends further, to around 2031 and 2035, other significant markets are seeing earlier patent expiries.

* Canada: Several sources indicate that semaglutide patents have already expired or will expire imminently in Canada. This has paved the way for generic versions to become available as early as January 20262025年7月9日—Hims & Hers Health announced plans to expand to Canada in 2026. ·Hims will offer generic copies of semaglutide drugs inCanada as Novo Nordisk .... Some reports even suggest that drug companies in Canada are allowed to make lower-priced generic versions of Ozempic as of next week (referring to early January 2026).Generic Ozempic coming to Canada: what the patent ... Companies like Sandoz and Apotex are expected to launch their products shortly after. It's noteworthy that Hims will offer generic copies of semaglutide drugs in Canada as Novo Nordisk’s market presence continues to evolve.

* India and China: These major markets are also anticipating the arrival of generic semaglutide in 2026. Novo Nordisk's patent on semaglutide expires in March in India, opening the door for the country's robust generic drug industry to enter the market.Generic Ozempic coming to Canada: what the patent expiry ... Dr.Dr Reddy's Plans to Launch Generic Semaglutide in 87 ... Reddy's Laboratories has been a prominent player, with plans to launch its generic semaglutide injection in India in March under the brand name, with Dr Reddy's readies day-1 launch of semaglutide generic on March 21. They have outlined ambitions to launch generics in 87 countries, including Canada, as early as March 2026. Similarly, Chinese drugmakers are preparing their generics as Novo Nordisk's semaglutide patent is set to expire in China in 2026. Zydus Lifesciences also plans to launch generic versions in India post-patent expiry.

* Europe: Patent expiries in "the majority of EU member states" are anticipated around 20312025年7月9日—Hims & Hers Health announced plans to expand to Canada in 2026. ·Hims will offer generic copies of semaglutide drugs inCanada as Novo Nordisk .... However, the exact timing can be complex due to varying patent laws and potential secondary protections2026年1月14日—Patent expires in 2031 in "the majority of EU member states," according to Novo. Canada — currently the second-largest market forsemaglutide, ....

* United Kingdom: While not directly tied to semaglutide, the recent availability of generic versions of liraglutide (another GLP-1 agonist) in the UK signals the broader trend towards accessible generic weight management and diabetes treatments.

* South Africa: It is likely that generic companies will seek to introduce generic semaglutide in South Africa in 2027, when the main patent on the drug is expected to expire.

The Role of Specific Companies and Potential Market Entrants

Several pharmaceutical companies are strategically positioning themselves to capitalize on the semaglutide patent expiriesOff-patent semaglutide in 2026: the next revolution in anti- ....

* Dr. Reddy's Laboratories: This Indian pharmaceutical giant is at the forefront, with a planned launch in India in March 2026Generic Ozempic can be made in Canada as of next week. .... Their ambition extends globally, aiming to launch generic semaglutide in 87 countries.

* Sandoz: A division of Novartis, Sandoz has expressed expectations for the market to take shape in the third quarter of 2026, depending on regulatory reviews. Their offering for diabetes only is projected for 2026, while Biocon hopes to offer generic semaglutide for both diabetes and weight loss by 2027.

* Sun Pharma: This company received DCGI approval in December 2025 for manufacturing and marketing semaglutide injections for adults with type 2 diabetes.Sun Pharma gets DCGI nod to make, market generic ...

* Zydus Lifesciences: Will launch generic versions of semaglutide injections for obesity and diabetes in India after patent expiry.2025年9月15日—Novo Nordisk has had a Canadian patent onsemaglutidefor years but got lax about the paperwork to maintain it until its “natural” end in March ...

* Apotex: Alongside Sandoz, Apotex is also expected to be among the first to launch generic semaglutide in Canada in January 2026.

It is crucial to note that the FDA has not approved a generic version of Ozempic in the United States as of recent reportsHims & Hers offers generic semaglutide as Novo Nordisk .... A true generic version of Ozempic won't be available in the US until at least 2033, with some estimates pointing towards 2033 for patent expiry and potentially later due to secondary protectionsIndian drugmaker Dr Reddy's gearing up for March debut ....

Impact on Pricing and Accessibility

The influx of generic semaglutide is expected to lead to a significant reduction in drug costs. Analysts anticipate that generic versions will be priced roughly 50% cheaper than their brand-name counterparts. This price decrease will make these vital treatments more accessible to a wider patient population, addressing the unmet need for affordable obesity medicines in public sectors and for individuals struggling with the high cost of current therapies.

Navigating the Generic Entry

While a generic semaglutide is set to become more widely available, the precise timing and specific product offerings will will vary by region and regulatory approval processes. Patients and healthcare providers should stay informed about approvals and availability in their respective markets. The era of cheaper semaglutide is dawning, promising to revolutionize diabetes and weight management care globally.